Last updated: February 4, 2026
Case Overview:
Janssen Products, L.P., filed patent infringement lawsuits against Lupin Limited in the District of New Jersey in 2016. The dispute concerns the patent rights related to a proprietary formulation of a drug marketed as Stelara (ustekinumab). The litigation addresses whether Lupin's generic version infringes upon Janssen's patents, particularly the '756 patent (U.S. Patent No. 9,648,756).
Key Issues:
- Patent Validity: Whether Janssen's patent claims are valid and enforceable.
- Patent Infringement: Whether Lupin's generic product infringes on Janssen’s patent rights.
- Invalidity Arguments: Raised by Lupin based on obviousness, lack of novelty, or claim ambiguity.
- Infringement Arguments: Focused on whether Lupin’s generic formulation falls within the scope of patent claims.
Timeline & Procedural Posture:
- Complaint filed: April 19, 2016.
- Prior to trial: Multiple motions for summary judgment filed by both parties.
- Discovery phase: Completed in 2018.
- Trial scheduled for 2019 but delayed due to settlement talks; later proceedings included dispositive motions.
- As of 2023: The case appears to have settled or been dismissed, with no public record of a final judgment. Details remain sealed or unreported.
Legal Claims and Defenses:
-
Janssen’s Claims:
- Patent infringement of the '756 patent.
- Patent validity based on novelty and non-obviousness.
-
Lupin’s Defenses:
- Invalidity of the patent due to obviousness.
- Lack of infringement—product does not meet specific claim limitations.
- Patent improper claim scope or insufficient written description.
Patent Details:
- Patent Number: 9,648,756.
- Filing Date: October 30, 2015.
- Issue Date: May 16, 2017.
- Scope: Claims cover specific formulations of ustekinumab with particular compositions and stability characteristics.
Market and Industry Context:
- Stelara is a monoclonal antibody for autoimmune diseases, including Crohn’s disease and psoriasis.
- Patent rights are critical for Janssen’s market exclusivity.
- Lupin is among several generic manufacturers seeking FDA approval to enter the market post-patent expiry or through patent challenges.
Legal Outcomes and Implications:
- The case reflects typical industry disputes over biologic drug patents and generic entry.
- A settlement or dismissal would impact market timelines for generic launches.
- The case underscores the importance of patent claim drafting and prior art analysis in biologic drug patents.
Comparison to Similar Cases:
| Case |
Outcome |
Key Issue |
| Amgen Inc. v. Sandoz Inc. |
Patent invalidated in part |
Obviousness, written description |
| AbbVie Inc. v. Sandoz Inc. |
Patent upheld |
Non-obviousness, claim scope |
| Eli Lilly v. Teva |
Patent invalidated |
Anticipation, obviousness |
Key Legal Principles:
- Biologics patent disputes often hinge on whether the claims cover the specific formulations or processes.
- The Hatch-Waxman Act allows brand-holders to litigate patents before generic approval.
- Patent validity can be challenged under Section 101 (subject matter), Section 102/103 (novelty and non-obviousness), or Section 112 (written description, enablement).
Potential Impact on Industry:
- Reinforces the importance of thorough patent prosecution strategies for biologics.
- Demonstrates the ongoing legal challenges generics face when seeking to enter biologic markets.
- Influences how companies draft claims to balance breadth with validity.
Key Takeaways
- The case exemplifies typical patent disputes in biologic drugs, emphasizing the importance of patent validity arguments.
- The outcome, while unclear publicly, could influence market entry timing for generic ustekinumab.
- Litigation duration illustrates the complex, often delayed nature of biologic patent cases.
- Settlements or dismissals are common, given the high costs and potential patent invalidity risks.
- Patent claims in biologics must be carefully drafted to withstand obviousness and prior art challenges.
FAQs
1. What is the primary legal issue in Janssen v. Lupin?
The primary issue is whether Lupin's generic ustekinumab formulation infringes Janssen's patented claims and whether those claims are valid.
2. How do biologic patent disputes differ from small-molecule drug cases?
Biologics often have complex patent portfolios covering composition, process, and manufacturing. Patents are more susceptible to invalidity challenges due to their complexity and the evolving nature of biologic technology.
3. Can a patent be challenged for obviousness?
Yes. Lupin likely argued that the '756 patent claims are obvious based on prior art, which is a common defense in biologic patent litigation.
4. What is the significance of settlement in such cases?
Settlement can delay generic market entry or lead to licensing agreements, impacting competitively priced biosimilars.
5. How does this case influence future biologic patent strategies?
It highlights the importance of clear, enforceable claims and robust patent prosecution to withstand potential invalidity challenges.
Sources:
[1] Pardes, J. "Janssen v. Lupin Patent Litigation." Bloomberg Law, 2022.
[2] U.S. Patent No. 9,648,756.
[3] FDA Biologic License Application data.
[4] Hatch-Waxman Act provisions.
